Skip to main content

Genital Warts

6
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
5100%
+ 6 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Medigene
MedigeneGermany - Planegg-Martinsried
1 program
1
Polyphenon EPhase 41 trial
Active Trials
NCT01082302Completed43Est. Aug 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
2
9vHPV VaccinePhase 3Vaccine
9vHPV vaccinePhase 3Vaccine
Medical / Surgical TreatmentN/A
MSD
MSDIreland - Ballydine
3 programs
2
9vHPV VaccinePhase 3Vaccine1 trial
9vHPV vaccinePhase 3Vaccine1 trial
Medical / Surgical TreatmentN/A1 trial
Active Trials
NCT01192282Completed156Est. Aug 2012
NCT01651949Completed2,520Est. Aug 2014
NCT05314023Active Not Recruiting1,590Est. Feb 2029
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
GS-9191 ointmentPhase 11 trial
Active Trials
NCT00499967Completed202Est. Mar 2009
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
Medical / Surgical TreatmentN/A
9vHPV VaccinePHASE_3Vaccine
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
GS-9191 ointmentPHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
MedigenePolyphenon E
MSD9vHPV vaccine
MSD9vHPV Vaccine
Kite PharmaGS-9191 ointment
MSDMedical / Surgical Treatment

Clinical Trials (5)

Total enrollment: 4,511 patients across 5 trials

NCT01082302MedigenePolyphenon E

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

Start: Jan 2010Est. completion: Aug 201043 patients
Phase 4Completed
NCT05314023MSD9vHPV vaccine

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Start: May 2022Est. completion: Feb 20291,590 patients
Phase 3Active Not Recruiting
NCT01651949MSD9vHPV Vaccine

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Start: Oct 2012Est. completion: Aug 20142,520 patients
Phase 3Completed
NCT00499967Kite PharmaGS-9191 ointment

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Start: Aug 2007Est. completion: Mar 2009202 patients
Phase 1Completed
NCT01192282MSDMedical / Surgical Treatment

Typing of Human Papilloma Virus (HPV) From Female Genital Warts

Start: Apr 2010Est. completion: Aug 2012156 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.